{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:56:04Z","timestamp":1789127764587,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10072-025-08154-2","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:12:31Z","timestamp":1744125151000},"page":"3427-3430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Critical issues in the use of edaravone for the treatment of amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-5355","authenticated-orcid":false,"given":"Hung Youl","family":"Seok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"8154_CR1","doi-asserted-by":"publisher","unstructured":"Al-Khayri JM, Ravindran M, Banadka A, Vandana CD, Priya K, Nagella P, Kukkemane K (2024) Amyotrophic lateral sclerosis: insights and new prospects in disease pathophysiology, biomarkers and therapies. Pharmaceuticals (Basel) 17(10). https:\/\/doi.org\/10.3390\/ph17101391","DOI":"10.3390\/ph17101391"},{"key":"8154_CR2","doi-asserted-by":"publisher","first-page":"108518","DOI":"10.1016\/j.mrrev.2024.108518","volume":"794","author":"R Sharma","year":"2024","unstructured":"Sharma R, Khan Z, Mehan S, Das Gupta G, Narula AS (2024) Unraveling the multifaceted insights into amyotrophic lateral sclerosis: genetic underpinnings, pathogenesis, and therapeutic horizons. Mutat Res Rev Mutat Res 794:108518. https:\/\/doi.org\/10.1016\/j.mrrev.2024.108518","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"2","key":"8154_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK (2019) Riluzole and Edaravone: A Tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733\u2013748. https:\/\/doi.org\/10.1002\/med.21528","journal-title":"Med Res Rev"},{"issue":"7","key":"8154_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"G Writing","year":"2017","unstructured":"Writing G, Edaravone ALSSG (2017) Safety and efficacy of Edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505\u2013512. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1","journal-title":"Lancet Neurol"},{"issue":"sup1","key":"8154_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/21678421.2017.1363780","volume":"18","author":"Edaravone Als 16 Study G","year":"2017","unstructured":"Edaravone Als 16 Study G (2017) A post-hoc subgroup analysis of outcomes in the first phase III clinical study of Edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 18(sup1):11\u201319. https:\/\/doi.org\/10.1080\/21678421.2017.1363780","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"8154_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10072-018-3653-2","volume":"40","author":"L Luo","year":"2019","unstructured":"Luo L, Song Z, Li X, Huiwang, Zeng Y, Qinwang, Meiqi, He J (2019) Efficacy and safety of Edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci 40(2):235\u2013241. https:\/\/doi.org\/10.1007\/s10072-018-3653-2","journal-title":"Neurol Sci"},{"issue":"10","key":"8154_CR7","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","volume":"44","author":"AZ Nourelden","year":"2023","unstructured":"Nourelden AZ, Kamal I, Hagrass AI, Tawfik AG, Elhady MM, Fathallah AH, Eshag MME, Zaazouee MS (2023) Safety and efficacy of Edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci 44(10):3429\u20133442. https:\/\/doi.org\/10.1007\/s10072-023-06869-8","journal-title":"Neurol Sci"},{"issue":"4","key":"8154_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.4103\/aian.aian_1083_21","volume":"25","author":"S Samadhiya","year":"2022","unstructured":"Samadhiya S, Sardana V, Bhushan B, Maheshwari D, Goyal R, Pankaj (2022) Assessment of therapeutic response of Edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients. Ann Indian Acad Neurol 25(4):692\u2013697. https:\/\/doi.org\/10.4103\/aian.aian_1083_21","journal-title":"Ann Indian Acad Neurol"},{"issue":"sup1","key":"8154_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/21678421.2017.1361441","volume":"18","author":"Writing Group On Behalf Of The Edaravone Als 18 Study G","year":"2017","unstructured":"Writing Group On Behalf Of The Edaravone Als 18 Study G (2017) Exploratory double-blind, parallel-group, placebo-controlled study of Edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener 18(sup1):40\u201348. https:\/\/doi.org\/10.1080\/21678421.2017.1361441","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"21","key":"8154_CR10","doi-asserted-by":"publisher","first-page":"e26127","DOI":"10.1097\/MD.0000000000026127","volume":"100","author":"A Kakimoto","year":"2021","unstructured":"Kakimoto A, Ishizaki M, Ueyama H, Maeda Y, Ueda M (2021) Renal function in amyotrophic lateral sclerosis patients on long-term treatment with Edaravone. Med (Baltim) 100(21):e26127. https:\/\/doi.org\/10.1097\/MD.0000000000026127","journal-title":"Med (Baltim)"},{"issue":"1","key":"8154_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12883-022-02788-x","volume":"22","author":"JM Park","year":"2022","unstructured":"Park JM, Park D, Kim HJ, Park JS (2022) Long-term outcomes of Edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study. BMC Neurol 22(1):260. https:\/\/doi.org\/10.1186\/s12883-022-02788-x","journal-title":"BMC Neurol"},{"issue":"4","key":"8154_CR12","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10072-021-05634-z","volume":"43","author":"J Ma","year":"2022","unstructured":"Ma J, Pang X, Huang S, Zhang J, Wang J, Zhao R, Chang X, Guo J, Zhang W (2022) Genetic analysis in Chinese patients with Familial or young-onset amyotrophic lateral sclerosis. Neurol Sci 43(4):2579\u20132587. https:\/\/doi.org\/10.1007\/s10072-021-05634-z","journal-title":"Neurol Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08154-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:28:56Z","timestamp":1752643736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08154-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["8154"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08154-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}